Intellia Therapeutics, Inc.
NTLA
$12.35
$0.151.23%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -0.46% | 5.47% | -0.07% | 11.44% | 11.30% |
| Total Depreciation and Amortization | -63.39% | 21.86% | 99.51% | -0.96% | -2.65% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -30.73% | 32.57% | -20.76% | -12.24% | -44.54% |
| Change in Net Operating Assets | -7,623.28% | -88.80% | 122.19% | 66.20% | -2,981.57% |
| Cash from Operations | -69.37% | 9.90% | 22.81% | 33.11% | -74.81% |
| Capital Expenditure | 37.30% | -334.48% | 87.87% | 67.48% | 25.08% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 140.02% | 3,984.83% | -100.66% | 12.71% | -37.68% |
| Cash from Investing | 140.83% | 3,815.79% | -100.69% | 13.34% | -37.76% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,597.98% | -98.28% | 683.90% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,597.98% | -98.28% | 683.90% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 56.08% | -206.87% | 69.63% | 140.18% | -179.49% |